【醫藥護人員場】9. Long-term Treatment Outcomes for Localized Prostate Cancer by Risk Group Stratification in Taiwan-冷凍治療

00:00 1.
Long-term Treatment Outcomes for Patients with Localized Prostate Cancer in Taiwan – Cryoablation (冷凍治療)
00:04 2.
Primary total cryoablation cohort
00:48 3.
Clinicopathological Parameters (Primary Cryo, N=223)
01:22 4.
Disease-Free Survival (Phoenix criteria)(Primary Total Cryo, N=223)
01:51 5.
Disease-Free Survival (Phoenix criteria)(Primary Total Cryo, N=223)
02:18 6.
Disease-Free Survival (Phoenix criteria)NTUH v.s. COLD
02:30 7.
Disease-Free Survival (Phoenix criteria)NTUH v.s. COLD
02:45 8.
L (2)
02:48 9.
Disease-Free Survival (Phoenix criteria)NTUH v.s. COLD
02:49 10.
L (2)
03:19 11.
Effect of Adjuvant ADT on Disease-free survival
03:36 12.
Adjuvant ADT for high risk CaP:Prospective randomized trial
04:07 13.
Outcome: PSA Response
05:10 14.
Overall and Cancer-Specific Survival(Primary Total Cryo, N=223)
05:48 15.
Complications of Cryoablation
06:34 16.
Complications of Cryoablation
06:49 17.
Urinary Incontinence (any pad use)
07:01 18.
Urinary Incontinence (any pad use)
07:25 19.
Urinary Incontinence (any pad use)
07:26 20.
Other Complications (Primary Cryo, N=233)(Grade II)
08:05 21.
Conclusion
08:29 22.
Thank you for your attention!

未登入或權限不足!

講者：陳忠信

日期：2016-05-10

觀看: 1146

00:00 1.
Long-term Treatment Outcomes for Patients with Localized Prostate Cancer in Taiwan – Cryoablation (冷凍治療)
00:04 2.
Primary total cryoablation cohort
00:48 3.
Clinicopathological Parameters (Primary Cryo, N=223)
01:22 4.
Disease-Free Survival (Phoenix criteria)(Primary Total Cryo, N=223)
01:51 5.
Disease-Free Survival (Phoenix criteria)(Primary Total Cryo, N=223)
02:18 6.
Disease-Free Survival (Phoenix criteria)NTUH v.s. COLD
02:30 7.
Disease-Free Survival (Phoenix criteria)NTUH v.s. COLD
02:45 8.
L (2)
02:48 9.
Disease-Free Survival (Phoenix criteria)NTUH v.s. COLD
02:49 10.
L (2)
03:19 11.
Effect of Adjuvant ADT on Disease-free survival
03:36 12.
Adjuvant ADT for high risk CaP:Prospective randomized trial
04:07 13.
Outcome: PSA Response
05:10 14.
Overall and Cancer-Specific Survival(Primary Total Cryo, N=223)
05:48 15.
Complications of Cryoablation
06:34 16.
Complications of Cryoablation
06:49 17.
Urinary Incontinence (any pad use)
07:01 18.
Urinary Incontinence (any pad use)
07:25 19.
Urinary Incontinence (any pad use)
07:26 20.
Other Complications (Primary Cryo, N=233)(Grade II)
08:05 21.
Conclusion
08:29 22.
Thank you for your attention!

【醫藥護人員場】9. Long-term Treatment Outcomes for Localized Prostate Cancer by Risk Group Stratification in Taiwan-冷凍治療

長度: 08:38, 瀏覽: 1147, 最近修訂: 2017-05-09

演講時間：10:30-11:30

講者：陳忠信醫師

現任職位/稱：

臺大醫院泌尿部主治醫師
臺大醫學院泌尿科助理教授
臺灣楓城泌尿學會理事
臺大醫學院臨床醫學研究所博士

00:00 1.
Long-term Treatment Outcomes for Patients with Localized Prostate Cancer in Taiwan – Cryoablation (冷凍治療)
00:04 2.
Primary total cryoablation cohort
00:48 3.
Clinicopathological Parameters (Primary Cryo, N=223)
01:22 4.
Disease-Free Survival (Phoenix criteria)(Primary Total Cryo, N=223)
01:51 5.
Disease-Free Survival (Phoenix criteria)(Primary Total Cryo, N=223)
02:18 6.
Disease-Free Survival (Phoenix criteria)NTUH v.s. COLD
02:30 7.
Disease-Free Survival (Phoenix criteria)NTUH v.s. COLD
02:45 8.
L (2)
02:48 9.
Disease-Free Survival (Phoenix criteria)NTUH v.s. COLD
02:49 10.
L (2)
03:19 11.
Effect of Adjuvant ADT on Disease-free survival
03:36 12.
Adjuvant ADT for high risk CaP:Prospective randomized trial
04:07 13.
Outcome: PSA Response
05:10 14.
Overall and Cancer-Specific Survival(Primary Total Cryo, N=223)
05:48 15.
Complications of Cryoablation
06:34 16.
Complications of Cryoablation
06:49 17.
Urinary Incontinence (any pad use)
07:01 18.
Urinary Incontinence (any pad use)
07:25 19.
Urinary Incontinence (any pad use)
07:26 20.
Other Complications (Primary Cryo, N=233)(Grade II)
08:05 21.
Conclusion
08:29 22.
Thank you for your attention!

位置

資料夾名稱

2016臺大攝護祭-醫藥護人員場

發表人

系統管理者

單位

泌尿部

建立

2016-05-10 12:32:00

最近修訂

2017-05-09 09:59:11

長度

08:38